信邦制药10月16日获融资买入3659.33万元，融资余额2.60亿元

Group 1 - The core viewpoint of the news is that Xinpang Pharmaceutical has shown a significant increase in stock price and trading volume, indicating potential investor interest and market activity [1] - On October 16, Xinpang Pharmaceutical's stock rose by 3.20%, with a trading volume of 418 million yuan, and a net financing purchase of 447.46 million yuan [1] - As of October 16, the total balance of margin trading for Xinpang Pharmaceutical was 261 million yuan, with a financing balance of 260 million yuan, accounting for 3.45% of the circulating market value, which is below the 30% percentile level over the past year [1] Group 2 - As of June 30, the number of shareholders for Xinpang Pharmaceutical was 66,700, a decrease of 0.41% from the previous period, while the average circulating shares per person increased by 4.50% to 28,904 shares [2] - For the first half of 2025, Xinpang Pharmaceutical reported a revenue of 2.845 billion yuan, a year-on-year decrease of 6.62%, and a net profit attributable to shareholders of 107 million yuan, also down by 6.69% [2] Group 3 - Since its A-share listing, Xinpang Pharmaceutical has distributed a total of 763 million yuan in dividends, with 402 million yuan distributed over the past three years [3] - As of June 30, 2025, among the top ten circulating shareholders, Hong Kong Central Clearing Limited held 21.8619 million shares, an increase of 1.6029 million shares from the previous period [3]